- Home
- STRO vs PSNL Comparison
STRO vs PSNL Comparison
Compare STRO & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- PSNL
- Stock Information
- Founded
- STRO 2003
- PSNL 2011
- Country
- STRO United States
- PSNL United States
- Employees
- STRO N/A
- PSNL N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- PSNL Medical Specialities
- Sector
- STRO Health Care
- PSNL Health Care
- Exchange
- STRO Nasdaq
- PSNL Nasdaq
- Market Cap
- STRO 292.6M
- PSNL 321.1M
- IPO Year
- STRO 2018
- PSNL 2019
- Fundamental
- Price
- STRO $2.89
- PSNL $3.89
- Analyst Decision
- STRO Strong Buy
- PSNL Strong Buy
- Analyst Count
- STRO 7
- PSNL 4
- Target Price
- STRO $12.14
- PSNL $6.81
- AVG Volume (30 Days)
- STRO 596.9K
- PSNL 845.3K
- Earning Date
- STRO 11-13-2024
- PSNL 11-06-2024
- Dividend Yield
- STRO N/A
- PSNL N/A
- EPS Growth
- STRO N/A
- PSNL N/A
- EPS
- STRO N/A
- PSNL N/A
- Revenue
- STRO $160,955,000.00
- PSNL $87,489,000.00
- Revenue This Year
- STRO N/A
- PSNL $14.85
- Revenue Next Year
- STRO N/A
- PSNL $4.19
- P/E Ratio
- STRO N/A
- PSNL N/A
- Revenue Growth
- STRO 230.90
- PSNL 24.05
- 52 Week Low
- STRO $2.13
- PSNL $1.02
- 52 Week High
- STRO $6.13
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- STRO 32.85
- PSNL 37.60
- Support Level
- STRO $4.01
- PSNL $4.15
- Resistance Level
- STRO $4.60
- PSNL $5.40
- Average True Range (ATR)
- STRO 0.36
- PSNL 0.50
- MACD
- STRO -0.06
- PSNL -0.10
- Stochastic Oscillator
- STRO 3.93
- PSNL 3.02
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.